Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice

Atherosclerosis

Volumn 198, Issue 1, 2008, Pages 77-84

  Braun, Anne ^a,b   Yesilaltay, Ayce ^a   Acton, Susan ^b   Broschat, Kay O ^c   Krul, Elaine S ^c   Napawan, Nida ^c   Stagliano, Nancy ^b   Krieger, Monty ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Cardium Pharmaceuticals Inc   (United States)

^c PFIZER INC   (United States)

Author keywords

ApoE; Atherosclerosis; Cholesterol; Coronary heart disease; Ezetimibe; Intestinal lipid absorption; Knockout mice; SR BI

Indexed keywords

APICAL SODIUM CODEPENDENT BILE TRANSPORTER INHIBITOR; APOLIPOPROTEIN E; BILE ACID; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SC 435; SCAVENGER RECEPTOR BI; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA ROOT; ARTICLE; CARDIOMEGALY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DEATH; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; HEART DISEASE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; KNOCKOUT MOUSE; LIFESPAN; LIPOPROTEIN METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS E; AZETIDINES; BILE ACIDS AND SALTS; BODY WEIGHT; CARDIOMEGALY; CHOLESTEROL; CORONARY ARTERY DISEASE; CYCLIC N-OXIDES; DISEASE MODELS, ANIMAL; EATING; FEMALE; FIBROSIS; HYPERCHOLESTEROLEMIA; INTESTINAL ABSORPTION; LIFE EXPECTANCY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SCAVENGER RECEPTORS, CLASS B; SURVIVAL RATE; TRIGLYCERIDES; TROPANES;

EID: 40949102355     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.10.012     Document Type: Article

References (34)

1. Kreisberg R.A., and Oberman A. Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies. J Clin Endocrinol Metab 87 (2002) 423-437
2. Burnett J.R., and Huff M.W. Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. Expert Opin Investig Drugs 15 (2006) 1337-1351
3. van Heek M., France C.F., Compton D.S., et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 283 (1997) 157-163
4. Rosenblum S.B., Huynh T., Afonso A., et al. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4- hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J Med Chem 41 (1998) 973-980
5. Gazi I.F., and Mikhailidis D.P. Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opin Ther Targets 10 (2006) 851-866
6. Davis Jr. H.R., Pula K.K., Alton K.B., Burrier R.E., and Watkins R.W. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism 50 (2001) 1234-1241
7. Davis Jr. H.R., Compton D.S., Hoos L., and Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in apoE knockout mice. Arterioscler Thromb Vasc Biol 21 (2001) 2032-2038
8. van Heek M., Compton D.S., and Davis H.R. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol 415 (2001) 79-84
9. van Heek M., Austin T.M., Farley C., et al. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes 50 (2001) 1330-1335
10. Repa J.J., Turley S.D., Quan G., and Dietschy J.M. Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption. J Lipid Res 46 (2005) 779-789
11. Kastelein J.J., Sager P.T., de Groot E., and Veltri E. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression (ENHANCE) trial. Am Heart J 149 (2005) 234-239
12. Davis Jr. H.R., Hoos L.M., Tetzloff G., et al. Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in apoE-/- mice. Arterioscler Thromb Vasc Biol 27 (2007) 841-849
13. Insull Jr. W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 99 (2006) 257-273
14. Rapp B., Beaudry, Napawan, and Keller. SC-435 is a potent inhibitor of the apical sodium co-dependent bile acid transporter (ASBT) in mice, rats, hamsters and dogs and reduces atherosclerotic lesions in apoE -/- mice. Proceedings of the XIV International Symposium on Drugs Affecting Lipid Metabolism. Fondazione Giovanni Lorenzini, Milan (2001)
15. West K.L., Ramjiganesh T., Roy S., Keller B.T., and Fernandez M.L. 1-[4-[4[(4R,5R)-3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydro xy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]butyl]-4-aza-1-azoniabicyclo[ 2.2.2]octane methanesulfonate (SC-435), an ileal apical sodium-codependent bile acid transporter inhibitor alters hepatic cholesterol metabolism and lowers plasma low-density lipoprotein-cholesterol concentrations in guinea pigs. J Pharmacol Exp Ther 303 (2002) 293-299
16. Huff M.W., Telford D.E., Edwards J.Y., et al. Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB. Arterioscler Thromb Vasc Biol 22 (2002) 1884-1891
17. Bhat B.G., Rapp S.R., Beaudry J.A., et al. Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE-/- mice by SC-435. J Lipid Res 44 (2003) 1614-1621
18. West K.L., Zern T.L., Butteiger D.N., Keller B.T., and Fernandez M.L. SC-435, an ileal apical sodium co-dependent bile acid transporter (ASBT) inhibitor lowers plasma cholesterol and reduces atherosclerosis in guinea pigs. Atherosclerosis 171 (2003) 201-210
19. Li H., Xu G., Shang Q., et al. Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7 alpha-hydroxylase. Metabolism 53 (2004) 927-932
20. Zhang S.H., Reddick R.L., Piedrahita J.A., and Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258 (1992) 468-471
21. Plump A.S., Smith J.D., Hayek T., et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71 (1992) 343-353
22. Braun A., Trigatti B.L., Post M.J., et al. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res 90 (2002) 270-276
23. Zhang S., Picard M.H., Vasile E., et al. Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice. Circulation 111 (2005) 3457-3464
24. Trigatti B., Rayburn H., Vinals M., et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci USA 96 (1999) 9322-9327
25. Karackattu S.L., Picard M.H., and Krieger M. Lymphocytes are not required for the rapid onset of coronary heart disease in scavenger receptor class B type I/apolipoprotein E double knockout mice. Arterioscler Thromb Vasc Biol 25 (2005) 803-808
26. Miettinen H.E., Rayburn H., and Krieger M. Abnormal lipoprotein metabolism and reversible female infertility in HDL receptor (SR-BI)-deficient mice. J Clin Invest 108 (2001) 1717-1722
27. Braun A., Zhang S., Miettinen H.E., et al. Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. Proc Natl Acad Sci USA 100 (2003) 7283-7288
28. Telford D.E., Edwards J.Y., Lipson S.M., et al. Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB. J Lipid Res 44 (2003) 943-952
29. Karackattu S.L., Trigatti B., and Krieger M. Hepatic lipase deficiency delays atherosclerosis, myocardial infarction, and cardiac dysfunction and extends lifespan in SR-BI/apolipoprotein E double knockout mice. Arterioscler Thromb Vasc Biol 26 (2006) 548-554
30. Frey N., and Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65 (2003) 45-79
31. Holm T.M., Braun A., Trigatti B.L., et al. Failure of red blood cell maturation in mice with defects in the high-density lipoprotein receptor SR-BI. Blood 99 (2002) 1817-1824
32. Deng Y.M., Wu B.J., Witting P.K., and Stocker R. Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1. Circulation 110 (2004) 1855-1860
33. Heinecke J.W. Lipoprotein oxidation in cardiovascular disease: chief culprit or innocent bystander?. J Exp Med 203 (2006) 813-816
34. Barter P.J., and Rye K.A. Cholesteryl ester transfer protein, high-density lipoprotein and arterial disease. Curr Opin Lipidol 12 (2001) 377-382